Get the Stockscreener App
0.7629
4.17%
-0.0332
After Hours:
.78
0.0171
+2.24%
Century Therapeutics Inc stock is traded at $0.7629, with a volume of 495.23K.
It is down -4.17% in the last 24 hours and down -27.34% over the past month.
Century Therapeutics Inc is a biotechnology company specializes in leveraging adult stem cells to develop advanced cell therapy products targeting cancer, autoimmune, and inflammatory diseases. Their innovative approach involves a genetically engineered allogeneic cell therapy platform comprising induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and cutting-edge manufacturing capabilities. This comprehensive platform aims to overcome the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and minimizing development and supply risks.
See More
Previous Close:
$0.7961
Open:
$0.7917
24h Volume:
495.23K
Relative Volume:
0.82
Market Cap:
$64.87M
Revenue:
$2.24M
Net Income/Loss:
$-136.67M
P/E Ratio:
-0.3331
EPS:
-2.29
Net Cash Flow:
$-102.08M
1W Performance:
-10.25%
1M Performance:
-27.34%
6M Performance:
-57.38%
1Y Performance:
-83.23%
1-Day Range:
$0.7545
$0.803
1-Week Range:
$0.7537
$0.8888
52-Week Range:
$0.7537
$5.51
Century Therapeutics Inc Stock (IPSC) Company Profile
Name
Century Therapeutics Inc
Sector
Industry
Phone
215-981-4000
Address
25 N 38TH STREET, 11TH FLOOR, PHILADELPHIA
Compare IPSC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IPSC
Century Therapeutics Inc
|
0.7629 | 64.87M | 2.24M | -136.67M | -102.08M | -2.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.16 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.07 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
657.97 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.25 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.94 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Century Therapeutics Inc Stock (IPSC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-08-24 | Initiated | Rodman & Renshaw | Buy |
| Aug-28-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-27-22 | Initiated | Chardan Capital Markets | Buy |
| Oct-31-22 | Initiated | Guggenheim | Buy |
| Oct-10-22 | Initiated | Canaccord Genuity | Buy |
| May-23-22 | Initiated | H.C. Wainwright | Buy |
| May-12-22 | Initiated | William Blair | Mkt Perform |
| Jul-13-21 | Initiated | BofA Securities | Buy |
| Jul-13-21 | Initiated | JP Morgan | Overweight |
| Jul-13-21 | Initiated | Piper Sandler | Overweight |
View All
Century Therapeutics Inc Stock (IPSC) Latest News
Century Therapeutics SVP sells shares worth $273 to cover taxes By Investing.com - Investing.com South Africa
Century Therapeutics SVP sells shares worth $273 to cover taxes - Investing.com
Century Therapeutics COO Farid Adrienne sells $822 in stock - Investing.com
Financial Metrics Exploration: Understanding Century Therapeutics Inc (IPSC) Through Ratios - The Dwinnex
JPMorgan Chase & Co. Has $123,000 Holdings in Century Therapeutics, Inc. (NASDAQ:IPSC) - Defense World
Century Therapeutics, Inc. (NASDAQ:IPSC) Sees Large Growth in Short Interest - MarketBeat
Century Therapeutics, Inc. (NASDAQ:IPSC) Receives $10.00 Consensus PT from Brokerages - Defense World
Barclays PLC Increases Stock Position in Century Therapeutics, Inc. (NASDAQ:IPSC) - Defense World
Century Therapeutics Partners with Experts for New Trial on Autoimmune Diseases - MyChesCo
Brokerages Set Century Therapeutics, Inc. (NASDAQ:IPSC) Price Target at $10.00 - MarketBeat
Century Therapeutics (NASDAQ:IPSC) Receives "Buy" Rating from Guggenheim - MarketBeat
HC Wainwright Reiterates Buy Rating for Century Therapeutics (NASDAQ:IPSC) - MarketBeat
Century Therapeutics launches cell therapy trial for autoimmune diseases - MSN
4 Analysts Have This To Say About Century Therapeutics - Benzinga
Century Therapeutics Announces Investigator-Initiated Phase - GlobeNewswire
Century Therapeutics Pioneers First iPSC-Derived NK Cell Therapy Trial for Autoimmune Diseases - StockTitan
Layoff Tracker: Notch Therapeutics to ‘Significantly Reduce’ Workforce - BioSpace
Century Therapeutics, Inc. (NASDAQ:IPSC) Short Interest Up 14.0% in December - Defense World
Short Interest in Century Therapeutics, Inc. (NASDAQ:IPSC) Increases By 14.0% - MarketBeat
Jane Street Group LLC Sells 62,588 Shares of Century Therapeutics, Inc. (NASDAQ:IPSC) - Defense World
JPMorgan Chase & Co. Boosts Stake in Costamare Inc. (NYSE:CMRE) - Defense World
Century Therapeutics Unveils Advances in Cell Therapies - TipRanks
Geode Capital Management LLC Raises Stake in Outlook Therapeutics, Inc. (NASDAQ:OTLK) - Defense World
Geode Capital Management LLC Purchases 32,614 Shares of Century Therapeutics, Inc. (NASDAQ:IPSC) - Defense World
Pre-market Movers: SANA, SLDB, JSPR, DRIO... - RTTNews
Century Therapeutics, Inc. (NASDAQ:IPSC) Shares Purchased by State Street Corp - Defense World
Pre-market Movers: ONCO, COEP, NUVB, SPRC... - RTTNews
Short Interest in Century Therapeutics, Inc. (NASDAQ:IPSC) Declines By 5.6% - MarketBeat
Century Therapeutics (NASDAQ:IPSC) Given New $4.00 Price Target at Piper Sandler - Defense World
Piper Sandler supports Century shares with Overweight rating as CAR-iNK study progresses - Investing.com UK
Century Therapeutics Inc receives Investment Bank Analyst Rating Update By Investing.com - Investing.com Nigeria
Charles Schwab Investment Management Inc. Sells 43,049 Shares of Century Therapeutics, Inc. (NASDAQ:IPSC) - Defense World
Deal Watch: Merck Decides Better Late Than Never In GLP-1 Deal With Hansoh - Citeline News & Insights
Philadelphia cell therapy developer loses Big Pharma partnership valued at over $3B - The Business Journals
BMS’ Cost-Cutting Campaign Claims Collabs With Immatics, Century - BioSpace
Century Therapeutics ends collaboration with Bristol-Myers Squibb - Investing.com
Century Therapeutics ends collaboration with Bristol-Myers Squibb By Investing.com - Investing.com Australia
Fmr LLC Sells 428,768 Shares of Century Therapeutics, Inc. (NASDAQ:IPSC) - MarketBeat
Fmr LLC Cuts Stake in Century Therapeutics, Inc. (NASDAQ:IPSC) - Defense World
Century Therapeutics Faces Termination of BMS Agreement - TipRanks
Century Therapeutics (NASDAQ:IPSC) Trading Down 4.3%Here's Why - MarketBeat
Century Therapeutics Inc Stock (IPSC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):